LUMICEF® (brodalumab) is a recombinant fully human monoclonal antibody and the only biologic treatment for moderate to severe plaque psoriasis that selectively targets the IL-17 receptor subunit A. By binding to IL- 17RA, it inhibits the biological activity of IL-17A, IL-17C, IL-17F, IL-17E (IL-25) and heterodimeric IL-17A/F which are actively enrolled in the pathogenesis of plaque psoriasis. By blocking the biological activity of these proinflammatory cytokines, LUMICEF® inhibits inflammation and improves the clinical symptoms significantly associated with psoriasis.
This page features main products from Kyowa Kirin worldwide portfolio and may not be available in all countries or regions, or may be approved for different indications, in different dosages, or in different strengths. In general, those products are available only by prescription through local healthcare professionals.
Please visit our local country or region website for local information: